Paper Details

  1. Home
  2. Paper Details

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.

Author: ChenWei-Wen, ChiouHui-Ling, HuangWei-Chang, HuangYi-Wen, LinChing-Hsiung, TsaoShih-Ming, YangShun-Fa, YangWen-Ta, YuYa-Yen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Weekly rifapentine and isoniazid therapy (3HP) is a common treatment for latent tuberculosis infection (LTBI). This study investigated the association between major adverse drug reactions (ADRs) and drug metabolic enzyme polymorphisms in patients receiving the 3HP regimen. Results showed that certain polymorphisms in CYP2C19 and CYP2E1 were associated with increased ADR risk.
Paper Details　
Original Abstract of the Article :
Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981901/

データ提供：米国国立医学図書館（NLM）

Genetic Polymorphisms and Adverse Drug Reactions: A Case Study in Latent Tuberculosis Treatment

This study explores the association between genetic polymorphisms in drug metabolic enzymes and the risk of adverse drug reactions (ADRs) in patients receiving rifapentine and isoniazid therapy for latent tuberculosis infection (LTBI). The researchers found that specific genetic variations in CYP2C19 and CYP2E1 genes were associated with an increased risk of ADRs. This study highlights the importance of considering genetic factors in optimizing medication regimens for LTBI treatment.

Optimizing Treatment and Minimizing Risks

The findings of this study provide valuable insights into the potential role of genetic factors in predicting and managing ADRs in LTBI patients. The researchers' identification of specific genetic variations associated with ADRs suggests that personalized treatment approaches, considering individual genetic profiles, may be beneficial in minimizing ADRs and improving patient outcomes.

The Importance of Personalized Medicine

This study emphasizes the importance of personalized medicine in tailoring treatment to the individual. The authors' findings demonstrate that understanding an individual's genetic makeup can be crucial in predicting and preventing ADRs, leading to more effective and safe treatment outcomes. Just as a camel must adapt to the unique challenges of the desert, healthcare professionals need to tailor their approaches to meet the individual needs of their patients.

Dr.Camel's Conclusion

This research highlights the importance of understanding the individual's genetic landscape in optimizing medical care. Just as a camel adapts to the diverse environments of the desert, we need to adapt our treatment approaches to account for the unique genetic makeup of each patient. This study is a reminder that personalized medicine is key to improving patient safety and achieving better outcomes.

Date :
  1. Date Completed 2020-06-08
  2. Date Revised 2020-06-08
Further Info :

Pubmed ID

31892222

DOI: Digital Object Identifier

PMC6981901

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.